SEARCH:   Advanced

Blood, 15 June 2004, Vol. 103, No. 12, pp. 4562-4564. Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-09-3352. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-09-3352v1 103/12/4562    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fabris, F. Articles by Girolami, A. Search for Related Content PubMed PubMed Citation Articles by Fabris, F. Articles by Girolami, A. Related Collections Hemostasis, Thrombosis, and Vascular Biology Immunobiology Brief Reports Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Brief report Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura Fabrizio Fabris, Raffaella Scandellari, Elisabetta Ruzzon, Maria Luigia Randi, Guido Luzzatto, and Antonio Girolami From the Department of Medical and Surgical Sciences, University of Padua Medical School, Padova, Italy. There were 50 consecutive idiopathic thrombocytopenic purpura (ITP) adult patients (platelet count < 100 x 109/L) grouped according to positivity or negativity of a solid-phase modified antigen capture enzyme-linked immunosorbent assay (ELISA) test (MACE) against glycoprotein IIb/IIIa (GPIIb/IIIa), Ib/IX, and IIa/IIIa. Observation started on the day of MACE assay and lasted at least 6 months. Clinical worsening was defined as the need for starting or modifying therapy because of thrombocytopenia lower than 20 x 109/L or patient admission due to bleeding symptoms. MACE-positive patients had a higher probability of clinical worsening than MACE-negatives (P < .004). The proportion of patients worsening was 18 (72%) of 25 among MACE-positives and 8 (32%) of 25 among MACE-negatives. The median time to clinical worsening was 2.1 months for MACE-positive patients and 27.7 months for MACE-negatives. The assay of specific platelet autoantibodies may be a useful prognostic tool for the clinical course of ITP. (Blood. 2004;103:4562-4564) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Antibodies redux Douglas B. Cines Blood 2004 103: 4380-4381. [Full Text] [PDF] This article has been cited by other articles: T. Gernsheimer Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis Oncologist, January 1, 2009; 14(1): 12 - 21. [Abstract] [Full Text] [PDF] D. S. Beardsley ITP in the 21st Century Hematology, January 1, 2006; 2006(1): 402 - 407. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020